Yves A. Dauvilliers

Yves A. Dauvilliers's AcademicInfluence.com Rankings

Yves A. Dauvilliers

Philosophy

#5869

World Rank

#8791

Historical Rank

Logic

#3078

World Rank

#4186

Historical Rank

philosophy Degrees

Yves A. Dauvilliers

Biology

#7910

World Rank

#10903

Historical Rank

Neuroscience

#1060

World Rank

#1102

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Yves A. Dauvilliers's Degrees

Doctorate Medicine University of Montpellier
PhD Neuroscience University of Montpellier

Why Is Yves A. Dauvilliers Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Yves A. Dauvilliers's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

National Sleep Foundation's sleep quality recommendations: first report☆ (2017) (629)
Narcolepsy with cataplexy (2007) (552)
Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study (2019) (482)
Age at onset of narcolepsy in two large populations of patients in France and Quebec (2001) (336)
Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. (2013) (307)
A single‐question screen for rapid eye movement sleep behavior disorder: A multicenter validation study (2012) (281)
Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. (2010) (280)
CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions (2003) (280)
Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial (2013) (273)
Polysomnographic diagnosis of idiopathic REM sleep behavior disorder (2010) (250)
Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment (2019) (239)
An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin−/− mice and patients (2008) (234)
EFNS guidelines on management of narcolepsy (2006) (232)
Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study (2015) (232)
Energy cost of walking and gait instability in healthy 65- and 80-yr-olds. (2003) (221)
Insomnia symptoms in older adults: associated factors and gender differences. (2011) (216)
Insomnia and daytime sleepiness are risk factors for depressive symptoms in the elderly. (2011) (213)
ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy (2013) (208)
Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. (2013) (199)
Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy (2010) (188)
Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. (2013) (187)
Post-H1N1 narcolepsy-cataplexy. (2010) (183)
Excessive sleepiness is predictive of cognitive decline in the elderly. (2012) (182)
Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. (2012) (175)
Hypertension and sleep: overview of a tight relationship. (2014) (173)
REM sleep behaviour disorder (2018) (172)
Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1 (2011) (172)
Clinical, polysomnographic and genome‐wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study (2013) (170)
Complex movement disorders at disease onset in childhood narcolepsy with cataplexy (2011) (168)
DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. (2014) (161)
Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset (2004) (161)
REM sleep characteristics in narcolepsy and REM sleep behavior disorder. (2007) (158)
Insomnia in patients with neurodegenerative conditions. (2007) (158)
Disrupted nighttime sleep in narcolepsy. (2013) (157)
Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis (2017) (156)
HLA and genetic susceptibility to sleepwalking (2003) (154)
Cataplexy—clinical aspects, pathophysiology and management strategy (2014) (146)
Excessive Daytime Sleepiness Is an Independent Risk Indicator for Cardiovascular Mortality in Community-Dwelling Elderly: The Three City Study (2009) (144)
Psychological health in central hypersomnias: the French Harmony study (2009) (143)
Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. (2014) (139)
Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. (2017) (131)
Genetics of normal and pathological sleep in humans. (2005) (128)
Effect of age on MSLT results in patients with narcolepsy–cataplexy (2004) (125)
Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial (2017) (123)
Clinical aspects and pathophysiology of narcolepsy (2003) (122)
[Narcolepsy with cataplexy]. (2008) (119)
Response to "Idiopathic hypersomnia: a diagnostic dilemma" (J. Montplaisir and L. Fantini). (2001) (117)
Insomnia, anxiety, and depression during the COVID-19 pandemic: an international collaborative study (2021) (116)
Clinical and polysomnographic course of childhood narcolepsy with cataplexy (2013) (113)
Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. (2014) (113)
Effect of cognitive behavioural therapy for insomnia on sleep architecture and sleep EEG power spectra in psychophysiological insomnia (2004) (111)
Clinical and practical considerations in the pharmacologic management of narcolepsy. (2015) (111)
HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. (2015) (111)
Excessive sleep duration and quality of life (2013) (110)
GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder (2015) (108)
Retinoic Acid Signaling Affects Cortical Synchrony During Sleep (2005) (108)
Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy (2017) (108)
Chiari malformation and sleep related breathing disorders (2007) (107)
Arousal reactions in sleepwalking and night terrors in adults: the role of respiratory events. (2002) (107)
A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France (2007) (106)
Family studies in insomnia. (2005) (105)
MAO-A and COMT polymorphisms and gene effects in narcolepsy (2001) (105)
A randomized study of solriamfetol for excessive sleepiness in narcolepsy (2019) (104)
Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. (2012) (103)
Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study. (2015) (102)
CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice (2016) (102)
NREM sleep parasomnias as disorders of sleep-state dissociation (2018) (101)
Recurrent hypersomnia: a review of 339 cases. (2011) (100)
Restless legs syndrome: update on pathogenesis (2013) (97)
Hypersomnia and depressive symptoms: methodological and clinical aspects (2013) (97)
Sleep disorders and their impacts on healthy, dependent, and frail older adults (2009) (95)
Periodic leg movements during sleep and wakefulness in narcolepsy (2007) (93)
Functional impairment in adult sleepwalkers: a case-control study. (2013) (92)
A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1 (2009) (88)
Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment (2009) (87)
Comorbidity and medication in REM sleep behavior disorder (2014) (87)
MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence (2018) (87)
Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology (2019) (87)
Operational definitions and algorithms for excessive sleepiness in the general population: implications for DSM-5 nosology. (2012) (87)
Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case–control study (2014) (87)
Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. (2013) (85)
High-dimensional single-cell analysis reveals the immune signature of narcolepsy (2016) (85)
Family history of insomnia in a population-based sample. (2007) (85)
No effect on cognitive function from daily mobile phone use (2005) (84)
Non-Dipping Blood Pressure Profile in Narcolepsy with Cataplexy (2012) (81)
Age-related changes in sleep in inbred mice are genotype dependent (2012) (81)
Interactions of the histamine and hypocretin systems in CNS disorders (2015) (81)
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma (2019) (80)
Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. (2013) (80)
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma (2019) (80)
Environmental risk factors for REM sleep behavior disorder (2012) (80)
Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions. (2012) (79)
Test–Retest Reliability of the Multiple Sleep Latency Test in Central Disorders of Hypersomnolence (2017) (77)
Insomnia in central neurologic diseases--occurrence and management. (2011) (77)
Age-at-onset in restless legs syndrome: a clinical and polysomnographic study. (2007) (75)
Prevalence and comorbidity of nocturnal wandering in the US adult general population (2012) (75)
Determinants of excessive daytime sleepiness in a French community‐dwelling elderly population (2007) (74)
From Phenomenology to Neurophysiological Understanding of Hallucinations in Children and Adolescents (2014) (74)
Impact of Obesity in Children with Narcolepsy (2013) (73)
Normal CSF Hypocretin-1 (Orexin A) Levels in Dementia with Lewy Bodies Associated with Excessive Daytime Sleepiness (2004) (73)
Daytime sleepiness and REM sleep characteristics in myotonic dystrophy: a case-control study. (2011) (72)
The clinical spectrum of childhood narcolepsy. (2017) (72)
Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process (2017) (71)
Hypothalamic immunopathology in anti-Ma-associated diencephalitis with narcolepsy-cataplexy. (2013) (70)
The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. (2012) (70)
Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. (2011) (70)
Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index (2014) (69)
Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts. (2020) (68)
Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. (2013) (68)
The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy. (2011) (67)
Aerobic determinants of the decline in preferred walking speed in healthy, active 65- and 80-year-olds (2004) (66)
Genes for normal sleep and sleep disorders (2005) (66)
Hypnotics and mortality in an elderly general population: a 12-year prospective study (2013) (65)
Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases (2019) (65)
Quality of Life in Children with Narcolepsy (2014) (64)
Executive Control of Attention in Narcolepsy (2012) (64)
SMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease (2019) (64)
Fatigue and daytime sleepiness in patients with myotonic dystrophy type 1: To lump or split? (2009) (64)
Month of birth as a risk factor for narcolepsy. (2003) (63)
Excessive daytime sleepiness and vascular events: The Three City Study (2012) (63)
Follow‐up of four narcolepsy patients treated with intravenous immunoglobulins (2006) (63)
Post-H 1 N 1 Narcolepsy-Cataplexy (2010) (63)
Depressive feelings in children with narcolepsy. (2014) (63)
Restless legs syndrome is frequent in narcolepsy with cataplexy patients. (2010) (63)
Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil (2002) (62)
Myotonic dystrophy type 1, daytime sleepiness and REM sleep dysregulation. (2012) (62)
Incidence, worsening and risk factors of daytime sleepiness in a population-based 5-year longitudinal study (2017) (62)
Kleine–Levin syndrome in 120 patients: Differential diagnosis and long episodes (2015) (62)
Sleep architecture, slow wave activity and sleep spindles in mild sleep disordered breathing (2003) (61)
Daytime Sleepiness and Myotonic Dystrophy (2013) (61)
Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity. (2016) (61)
Catechol-O-methyltransferase, dopamine, and sleep-wake regulation. (2015) (60)
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder (2020) (59)
Daytime Sleepiness in Parkinson’s Disease: A Reappraisal (2014) (59)
Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. (2018) (59)
Car Crashes and Central Disorders of Hypersomnolence: A French Study (2015) (58)
Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin (2010) (57)
Treatment Options for Narcolepsy (2016) (57)
POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project (2018) (57)
Decision making in narcolepsy with cataplexy. (2011) (56)
Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study (2019) (55)
Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study (2019) (55)
Insomnia, Daytime Sleepiness and Cardio-Cerebrovascular Diseases in the Elderly: A 6-Year Prospective Study (2013) (54)
Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies (2019) (54)
Histamine: neural circuits and new medications (2018) (53)
Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies (2013) (52)
Management of narcolepsy during pregnancy. (2013) (51)
Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome. (2013) (51)
A narcolepsy susceptibility locus maps to a 5Mb region of chromosome 21q (2004) (50)
From state dissociation to status dissociatus. (2016) (50)
Differential diagnosis in hypersomnia (2006) (50)
A brain PET study in patients with narcolepsy–cataplexy (2009) (50)
Very early onset AD with a de novo mutation in the presenilin 1 gene (Met 233 Leu) (2003) (50)
A multidimensional approach of impulsivity in adult attention deficit hyperactivity disorder (2015) (50)
A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1 (2004) (49)
Family history of idiopathic REM behavior disorder (2013) (49)
Hypersomnolence, Hypersomnia, and Mood Disorders (2017) (49)
Diagnostic criteria for disorders of arousal: A video‐polysomnographic assessment (2018) (48)
Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test. (2015) (48)
Kleine-Levin syndrome: An autoimmune hypothesis based on clinical and genetic analyses (2002) (47)
Periodic leg movements during sleep in narcoleptic patients with or without restless legs syndrome (2012) (46)
Impact of Astroglial Connexins on Modafinil Pharmacological Properties. (2016) (46)
Comorbidity between central disorders of hypersomnolence and immune-based disorders (2017) (45)
Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy (2014) (45)
Autonomic response to periodic leg movements during sleep in narcolepsy-cataplexy. (2011) (45)
Absence of γ‐aminobutyric acid‐a receptor potentiation in central hypersomnolence disorders (2016) (45)
Measurement of narcolepsy symptoms (2017) (44)
Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder (2020) (44)
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA‐ARIA) ‐ EIP on AHA Twinning Reference Site (GARD research demonstration project) (2018) (44)
A comprehensive rehabilitation program improves disease severity in patients with obstructive sleep apnea syndrome: a pilot randomized controlled study. (2014) (43)
Alternative diagnostic criteria for idiopathic hypersomnia: A 32‐hour protocol (2018) (42)
The European Narcolepsy Network (EU‐NN) database (2016) (42)
Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson's disease (2012) (42)
Lower wake resting sympathetic and cardiovascular activities in narcolepsy with cataplexy (2014) (42)
Recent advances in treatment for narcolepsy (2019) (42)
Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease (2016) (42)
Pressure reduction during exhalation in sleep apnea patients treated by continuous positive airway pressure. (2009) (42)
Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease (2021) (41)
Parkinson’s Disease Genetic Loci in Rapid Eye Movement Sleep Behavior Disorder (2015) (41)
Depression and Hypersomnia: A Complex Association. (2017) (40)
Impact of cytokine in type 1 narcolepsy: Role of pandemic H1N1 vaccination ? (2015) (39)
Non-24-Hour Sleep–Wake Rhythm Disorder in the Totally Blind: Diagnosis and Management (2017) (39)
European guideline and expert statements on the management of narcolepsy in adults and children (2021) (39)
Histamine and tele-methylhistamine quantification in cerebrospinal fluid from narcoleptic subjects by liquid chromatography tandem mass spectrometry with precolumn derivatization. (2011) (38)
High pain frequency in narcolepsy with cataplexy. (2011) (38)
Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy (2017) (37)
Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy (2017) (36)
Fine‐Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies (2020) (36)
Measurement of narcolepsy symptoms: the narcolepsy severity scale (2017) (36)
From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid (2016) (36)
Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial (2020) (36)
Widespread Hypermetabolism in Symptomatic and Asymptomatic Episodes in Kleine-Levin Syndrome (2014) (36)
Narcolepsy and Other Central Hypersomnias (2017) (35)
Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy (2018) (35)
Smoking, Alcohol, Drug Use, Abuse and Dependence in Narcolepsy and Idiopathic Hypersomnia: A Case-Control Study. (2016) (35)
Molecular genetics and treatment of narcolepsy (2006) (35)
Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: A case-control study (2014) (35)
ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice (2020) (34)
Evening-types show highest increase of sleep and mental health problems during the COVID-19 pandemic—multinational study on 19 267 adults (2021) (33)
Bi-allelic JAM2 Variants Lead to Early-Onset Recessive Primary Familial Brain Calcification (2020) (33)
Increased Immune Complexes of Hypocretin Autoantibodies in Narcolepsy (2010) (32)
Objective daytime sleepiness in patients with somnambulism or sleep terrors (2014) (32)
The distinguishing motor features of cataplexy: a study from video-recorded attacks (2017) (32)
Biallelic mutations in neurofascin cause neurodevelopmental impairment and peripheral demyelination (2019) (32)
Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning (2018) (32)
Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder (2018) (31)
Kleine-Levin syndrome in a 14-year-old girl: CSF hypocretin-1 measurements. (2006) (31)
Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial. (2016) (30)
Pain in Sleepwalking: A Clinical Enigma. (2015) (30)
Validation of Multiple Sleep Latency Test for the diagnosis of pediatric narcolepsy type 1 (2019) (30)
The dementia-associated APOE ε4 allele is not associated with rapid eye movement sleep behavior disorder (2017) (30)
Low Vitamin D in Narcolepsy with Cataplexy (2011) (30)
Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study (2018) (29)
Differences in Brain Morphological Findings between Narcolepsy with and without Cataplexy (2013) (29)
Restless legs syndrome and cardiovascular diseases: A case-control study (2017) (29)
Impact of acute administration of sodium oxybate on nocturnal sleep polysomnography and on multiple sleep latency test in narcolepsy with cataplexy. (2014) (29)
Sleep complaints and metabolic syndrome in an elderly population: the Three-City Study. (2014) (29)
Restless legs syndrome (2021) (29)
Management of Narcolepsy (2016) (28)
Ictal SPECT in patients with rapid eye movement sleep behaviour disorder. (2015) (28)
Sleep and daytime problems during the COVID-19 pandemic and effects of coronavirus infection, confinement and financial suffering: a multinational survey using a harmonised questionnaire (2021) (28)
Decision making in restless legs syndrome (2010) (28)
French consensus. Management of patients with hypersomnia: Which strategy? (2017) (28)
Sodium oxybate is an effective and safe treatment for narcolepsy. (2010) (28)
Preliminary results on CSF biomarkers for hypothalamic dysfunction in Kleine-Levin syndrome. (2015) (27)
Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's disease. (2014) (27)
Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy (2020) (26)
Daytime somnolence in adult sleepwalkers. (2013) (25)
Obstructive Sleep Apnea patients adhering to Continuous positive Airway Pressure: A randomized trial. (2020) (25)
Treatment options in narcolepsy (2013) (25)
[18F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia (2017) (25)
Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment (2017) (25)
Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease (2020) (25)
Cardiovascular disorders in narcolepsy: Review of associations and determinants. (2021) (25)
Hypocretin and human African trypanosomiasis. (2008) (25)
Effects of 1‐month withdrawal of ventilatory support in hypercapnic myotonic dystrophy type 1 (2017) (24)
Rare missense mutations in P2RY11 in narcolepsy with cataplexy (2017) (24)
Association between serum hepcidin level and restless legs syndrome (2018) (24)
Pharmacotherapy options for cataplexy (2013) (24)
Update on treatment for idiopathic hypersomnia (2018) (24)
The genetic basis of sleep disorders. (2008) (24)
Olfactory dysfunction in narcolepsy with cataplexy. (2010) (23)
GBA variants in REM sleep behavior disorder: a multicenter study (2019) (23)
Reward-based behaviors and emotional processing in human with narcolepsy-cataplexy (2013) (23)
Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations (2020) (23)
How our Dreams Changed During the COVID-19 Pandemic: Effects and Correlates of Dream Recall Frequency - a Multinational Study on 19,355 Adults (2021) (23)
Restless legs syndrome outside the blood-brain barrier--exacerbation by domperidone in Parkinson's disease. (2013) (23)
Clinical autonomic dysfunction in Narcolepsy Type 1. (2019) (22)
Restless legs syndrome in narcolepsy: a side effect of sodium oxybate? (2007) (22)
Melanin concentrating hormone in central hypersomnia. (2011) (22)
[Sleep in fibromyalgia: review of clinical and polysomnographic data]. (2001) (22)
Effect of psychostimulants on impulsivity and risk taking in narcolepsy with cataplexy. (2013) (22)
Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study (2017) (21)
Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. (2019) (21)
Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes (2009) (21)
Restless legs syndrome and iron deficiency in adults with attention-deficit/hyperactivity disorder. (2019) (21)
European guideline and expert statements on the management of narcolepsy in adults and children. (2021) (21)
Common and rare GCH1 variants are associated with Parkinson's disease (2019) (21)
LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. (2018) (20)
Cardiac Sympathetic Activity differentiates Idiopathic and Symptomatic Rapid Eye Movement Sleep Behaviour Disorder (2018) (20)
C9orf72 Repeat Expansions in Rapid Eye Movement Sleep Behaviour Disorder (2014) (20)
Circadian Rhythm Disturbances in the Blind (2018) (20)
Risk Factor Profile in Parkinson's Disease Subtype with REM Sleep Behavior Disorder. (2016) (20)
Sequencing of the GBA coactivator, Saposin C, in Parkinson disease (2018) (20)
Impact of genioplasty on mandibular growth during puberty. (2010) (19)
GBA variants in REM sleep behavior disorder (2020) (19)
Dissociation in circadian rhythms in a pseudohypersomnia form of fatal familial insomnia (2004) (19)
Hypersomnia (2005) (19)
Pitolisant for Daytime Sleepiness in Obstructive Sleep Apnea Patients Refusing CPAP: A Randomized Trial. (2020) (18)
Management of Narcolepsy in Adults (2010) (18)
Loss of the transcription factor Meis1 prevents sympathetic neurons target-field innervation and increases susceptibility to sudden cardiac death (2016) (18)
Measurement of symptoms in idiopathic hypersomnia: the idiopathic hypersomnia severity scale (2019) (18)
Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination (2018) (18)
Narcolepsy Severity Scale: A reliable tool assessing symptom severity and consequences. (2020) (18)
Narcolepsy and familial advanced sleep-phase syndrome: molecular genetics of sleep disorders. (2007) (18)
Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. (2017) (17)
MEIS1 variant as a determinant of autonomic imbalance in Restless Legs Syndrome (2017) (17)
Trajectories of sleep complaints from early midlife to old age: longitudinal modeling study. (2012) (17)
Kleine-Levin syndrome is associated with birth difficulties and genetic variants in the TRANK1 gene loci (2021) (17)
Efficacy of THN102 (a combination of modafinil and flecainide) on vigilance and cognition during 40‐hour total sleep deprivation in healthy subjects: Glial connexins as a therapeutic target (2019) (17)
Impaired histaminergic neurotransmission in children with narcolepsy type 1 (2018) (17)
The association between high risk of sleep apnea, comorbidities, and risk of COVID-19: a population-based international harmonized study (2021) (16)
Idiopathic Hypersomnia. (2020) (16)
Aerobic and functional capacities in a selected active population of European octogenarians. (2005) (16)
Improved sleep scoring in mice reveals human-like stages (2018) (16)
Nightmares in People with COVID-19: Did Coronavirus Infect Our Dreams? (2022) (16)
Hepcidin and ferritin levels in restless legs syndrome: a case–control study (2020) (16)
Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes (2008) (16)
Blood pressure profile and endothelial function in restless legs syndrome (2019) (16)
Socioeconomic impact of restless legs syndrome and inadequate restless legs syndrome management across European settings (2020) (16)
Ventilatory disorders and facial growth: benefits of early genioplasty. (2011) (16)
Disturbances in sleep, circadian rhythms and daytime functioning in relation to coronavirus infection and Long‐COVID – A multinational ICOSS study (2021) (16)
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study (2022) (15)
Risk Factors for Phenoconversion in Rapid Eye Movement Sleep Behavior Disorder (2022) (15)
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy (2021) (15)
Reduced brain amyloid burden in elderly patients with narcolepsy type 1 (2018) (15)
Daytime sleepiness in Parkinson's disease (2015) (15)
Measurement of symptoms in idiopathic hypersomnia (2019) (15)
Impact of sleep disturbances on kidney function decline in the elderly (2015) (15)
Predicting daytime sleepiness and fatigue: a 9-year prospective study in myotonic dystrophy type 1 (2019) (15)
Pharmacogenomics in the treatment of narcolepsy. (2003) (15)
Severity of narcolepsy among French of different ethnic origins (south of France and Martinique). (2002) (14)
Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy (2021) (14)
Narcolepsy risk loci are enriched in immune cells and suggest autoimmune modulation of the T cell receptor repertoire (2018) (14)
Disorders of Arousal in adults: new diagnostic tools for clinical practice (2019) (14)
Social Jetlag Changes During the COVID-19 Pandemic as a Predictor of Insomnia – A Multi-National Survey Study (2021) (14)
Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies (2018) (14)
Narcolepsy with cataplexy: Does age at diagnosis change the clinical picture? (2020) (14)
Maintenance of Wakefulness Test, real and simulated driving in patients with narcolepsy/hypersomnia. (2019) (13)
Increased perfusion in supplementary motor area during a REM sleep behaviour episode. (2011) (13)
Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants (2020) (13)
REVERSAL OF SYMPTOMATIC TUMORAL NARCOLEPSY, WITH NORMALIZATION OF CSF HYPOCRETIN LEVEL (2007) (13)
The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder (2016) (13)
Association of Inattention, Hyperactivity, and Hypersomnolence in Two Clinic-Based Adult Cohorts (2020) (13)
Exploration of cardiac sympathetic adrenergic nerve activity in narcolepsy (2019) (13)
A provisional tool for the measurement of sleep satisfaction (2018) (13)
Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP (13)
Vitamin D deficiency in type 1 narcolepsy: a reappraisal. (2017) (13)
Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2 p 14 and 16 q 12 . 1 (2017) (13)
Natural history of Excessive Daytime Sleepiness: A population-based 5-year longitudinal study. (2019) (13)
Maintenance of wakefulness test: how does it predict accident risk in patients with sleep disorders? (2020) (12)
Gut microbiota composition is associated with narcolepsy type 1 (2020) (12)
Absence of Relationship Between Self-Reported Sleep Measures and Amyloid Load in Elderly Subjects (2019) (12)
Familial Aggregation of Insomnia (2017) (12)
Disrupted nighttime sleep and sleep instability in narcolepsy. (2021) (12)
Association of CSF orexin-A levels and nocturnal sleep stability in patients with hypersomnolence (2020) (11)
Characteristics associated with hypersomnia and excessive daytime sleepiness identified by extended polysomnography recording. (2020) (11)
Is adult-onset attention deficit/hyperactivity disorder frequent in clinical practice? (2017) (11)
Sleepiness: Myotonic dystrophy and sleepiness (2011) (11)
Sleep inertia measurement with the psychomotor vigilance task in idiopathic hypersomnia. (2021) (11)
Hypocretin/Orexin, Sleep and Alzheimer's Disease. (2021) (11)
Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease (2020) (10)
Absence of NMDA receptor antibodies in the rare association between Type 1 Narcolepsy and Psychosis (2016) (10)
TOX3 Variants Are Involved in Restless Legs Syndrome and Parkinson’s Disease with Opposite Effects (2018) (10)
Autoantibody profiling on high-density protein microarrays for biomarker discovery in the cerebrospinal fluid. (2008) (10)
The orexin story, sleep and sleep disturbances (2022) (10)
Variants in the Niemann–Pick type C gene NPC1 are not associated with Parkinson's disease (2020) (10)
Sleep and dementia (2010) (10)
French consensus. Idiopathic hypersomnia: Investigations and follow-up. (2017) (10)
Corrigendum to “Increased perfusion in supplementary motor area during a REM sleep behaviour episode” [Sleep Med 12(5) (2011) 531–2] (2011) (10)
Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise (2019) (10)
Kleine‐Levin syndrome is associated with LMOD3 variants (2018) (10)
Persistence of deep-tendon reflexes during partial cataplexy. (2018) (10)
Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients (2022) (9)
Analysis of common and rare VPS13C variants in late-onset Parkinson disease (2020) (9)
RIC3 variants are not associated with Parkinson's disease in French-Canadians and French (2017) (9)
Effects of an individualized exercise training program on severity markers of obstructive sleep apnea syndrome: a randomised controlled trial. (2020) (9)
Understanding and approaching excessive daytime sleepiness (2022) (9)
Measurement of Narcolepsy Symptoms in School-Aged Children and Adolescents (2021) (9)
Sleep symptoms are essential features of long‐COVID – Comparing healthy controls with COVID‐19 cases of different severity in the international COVID sleep study (ICOSS‐II) (2022) (9)
A systematic analysis of ICSD-3 diagnostic criteria and proposal for further structured iteration. (2021) (9)
Correction: Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1 (2011) (9)
French consensus. Hypersomnolence: Evaluation and diagnosis. (2017) (8)
Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial (2020) (8)
Depression and suicidal thoughts in untreated and treated narcolepsy (2020) (8)
Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia. (2021) (8)
[Kleine-Levin syndrome: state of the art]. (2008) (8)
Facial expression recognition and emotional regulation in narcolepsy with cataplexy (2013) (8)
Impaired glycinergic transmission in hyperekplexia: a model of parasomnia overlap disorder (2019) (8)
[Neurodegenerative, autoimmune and genetic processes of human and animal narcolepsy]. (2003) (8)
New 2013 incidence peak in childhood narcolepsy: more than vaccination? (2020) (8)
Comprehensive Analysis of Familial Parkinsonism Genes in Rapid‐Eye‐Movement Sleep Behavior Disorder (2020) (8)
Cerebrospinal fluid monoamine levels in central hypersomnolence disorders. (2021) (8)
French consensus. Type 1 and type 2 narcolepsy: investigations and follow-up (2017) (8)
Novel Associations of BST1 and LAMP3 With REM Sleep Behavior Disorder (2021) (7)
[Narcolepsy with cataplexy in the child: clinical evaluation and therapeutical management]. (2008) (7)
CSF and serum ferritin levels in narcolepsy type 1 comorbid with restless legs syndrome (2019) (7)
PREDICTING SLEEP/WAKE PATTERNS FROM 3-AXIS ACCELEROMETRY USING DEEP LEARNING (2017) (7)
Corrigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Narcolepsy With Cataplexy (2021) (7)
Association study of essential tremor genetic loci in Parkinson's disease (2018) (7)
Narcolepsy with intermediate cerebrospinal level of hypocretin-1. (2021) (7)
Efficacy and safety of Jzp-258 In A Phase 3 Double-Blind, Placebo-Controlled, Randomised-Withdrawal Study In Adults With Narcolepsy With Cataplexy (2019) (6)
Linking clinical complaints and objective measures of Disrupted Nighttime Sleep in Narcolepsy type 1. (2022) (6)
Validation of the French Version of the Weiss Functional Impairment Rating Scale–Self-Report in a Large Cohort of Adult Patients With ADHD (2018) (6)
Circulating follicular helper T cells exhibit reduced ICOS expression and impaired function in narcolepsy type 1 patients. (2018) (6)
Kinesthetic stimulation for obstructive sleep apnea syndrome: An “on-off” proof of concept trial (2017) (6)
[Restless legs syndrome: a genetic disease?]. (2010) (6)
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder (2022) (6)
Time to find a biomarker in Kleine-Levin Syndrome. (2016) (6)
The major physiological functions during sleep (2003) (6)
Analysis of common and rare VPS13C variants in late onset Parkinson disease (2019) (6)
French consensus: Augmentation syndrome in restless legs syndrome. (2018) (6)
Metabolomics Signature of Patients With Narcolepsy (2021) (5)
[Physiopathology of idiopathic hypersomnia. Current studies and new orientations]. (2001) (5)
Excessive Daytime Sleepiness Is an Independent Risk Indicator for Cardiovascular Mortality in Community-Dwelling Elderly (2009) (5)
Shared T cell receptor chains in blood memory CD4+ T cells of narcolepsy type 1 patients. (2019) (5)
Rhythmic movement disorder associated with restless legs syndrome. (2012) (5)
Altered sleep-related blood pressure profile in hypocretin-deficient narcoleptic patients. (2012) (5)
Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis (2022) (5)
Sleep-related head jerks: towards a new movement disorder. (2020) (5)
Low cerebrospinal fluid hypocretin levels during sudden infant death syndrome (SIDS) risk period. (2017) (5)
Increased Blood Pressure Dipping in Restless Legs Syndrome With Rotigotine: A Randomized Trial (2020) (5)
Depressive Symptoms and Suicidal Thoughts in Restless Legs Syndrome (2022) (5)
Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. (2017) (5)
Symptom network analysis of the sleep disorders diagnostic criteria based on the clinical text of the ICSD‐3 (2021) (5)
Cerebrospinal fluid monoamine levels in central disorders of hypersomnolence (2021) (5)
[Appropriate medication prescribing in older people]. (2015) (5)
A randomized, placebo-controlled, phase 3 study of the safety and efficacy of solriamfetol (JZP-110) for the treatment of excessive sleepiness in patients with narcolepsy (2017) (4)
Knowledge Gaps in the Perioperative Management of Adults With Narcolepsy: A Call for Further Research. (2019) (4)
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial (2021) (4)
Video-Polysomnographic Assessment for the Diagnosis of Disorders of Arousal in Children (2020) (4)
French Language Online Cognitive Behavioral Therapy for Insomnia Disorder: A Randomized Controlled Trial (2019) (4)
Chapter 86 – Idiopathic Hypersomnia (2011) (4)
Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly (2022) (4)
The Impact of Narcolepsy and Its Treatment – A European Study (2008) (4)
0026 GENETIC LOCI IN PERIODIC HYPERSOMNIA/KLEINE-LEVIN SYNDROME TYPE (2017) (4)
[Immunological aspects of narcolepsy]. (2001) (4)
Current and future therapeutic approaches in narcolepsy (2011) (4)
[Normal organization of sleep and its changes during life]. (2019) (4)
Data-Driven Phenotyping of Central Disorders of Hypersomnolence With Unsupervised Clustering (2022) (4)
Histamine in murine narcolepsy: What do genetic and immune models tell us? (2021) (4)
Comorbid parasomnias in narcolepsy and idiopathic hypersomnia: more REM than NREM parasomnias. (2022) (4)
Clinical considerations for the diagnosis of idiopathic hypersomnia. (2022) (4)
Editorial: sleep and dementia. (2010) (4)
A comprehensive analysis of dominant and recessive parkinsonism genes in REM sleep behavior disorder (2020) (4)
Genome-wide association study of REM sleep behavior disorder identifies novel loci with distinct polygenic and brain expression effects (2021) (4)
Molecular genetics, circadian rhythms and sleep (2003) (4)
GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease (2022) (4)
Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects (2022) (4)
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial (2022) (3)
Device agnostic sleep-wake segment classification from wrist-worn accelerometry (2020) (3)
A double-blind, placebo-controlled, randomized-withdrawal, multicenter study of the efficacy and safety of sodium oxybate in pediatric subjects with narcolepsy with cataplexy (2017) (3)
Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy. (2021) (3)
50th anniversary of the ESRS in 2022-JSR special issue. (2022) (3)
Changes in cataplexy frequency by prior therapy in a phase 3, double-blind, placebo-controlled, randomised withdrawal study of JZP-258 in adults with narcolepsy with cataplexy (2019) (3)
Long-term safety and efficacy of daridorexant in patients with insomnia disorder (2022) (3)
Reply to Micoulaud-Franchi et al. Commentary on diagnosis of central disorders of hypersomnolence: From clinic to clinic via ontology and semantic analysis on a bullet point path. (2020) (3)
[NARCOLEPSY WITH CATAPLEXY: TYPE 1 NARCOLEPSY]. (2016) (3)
Increased blood pressure during the suggested immobilization test in Restless Legs Syndrome. (2020) (3)
SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder (2020) (3)
Disturbed nighttime sleep in children and adults with rhythmic movement disorder. (2020) (3)
Decreased fat oxidation during exercise in severe obstructive sleep apnoea syndrome. (2012) (3)
Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients. (2022) (3)
Definitions and epidemiology of insomnia (2017) (3)
Is the Muscle the Only Potential Target of Desipramine in Obstructive Sleep Apnea Syndrome? (2017) (3)
Prevalence of obstructive sleep apnoea in acute coronary syndrome: Routine screening in intensive coronary care units. (2017) (3)
Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials (2021) (3)
Reply to Maski K et al. commentary on diagnosis of central disorders of hypersomnolence: Challenges in defining central disorders of hypersomnolence. (2020) (3)
Challenges in diagnosing narcolepsy without cataplexy (2014) (3)
A series of eight cases of sleep-related psychogenic dissociative disorders and proposed updated diagnostic criteria. (2021) (3)
[Narcolepsy with cataplexy: an autoimmune disease?]. (2014) (3)
Early onset of sleep/wake disturbances in a progressive macaque model of Parkinson’s disease (2022) (2)
adults: a randomized controlled trial of exercise Etiology and modification of gait instability in older (2005) (2)
0675 A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE SAFETY AND EFFICACY OF JZP-110 FOR THE TREATMENT OF EXCESSIVE SLEEPINESS IN PATIENTS WITH NARCOLEPSY (2017) (2)
Self-perceived sleep during the Maintenance of Wakefulness Test: how does it predict accidental risk in patients with sleep disorders? (2021) (2)
Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder. (2021) (2)
Excessive daytime sleepiness and antipathogen drug consumption in the elderly: a test of the immune theory of sleep (2016) (2)
2018 worldwide survey of health-care providers caring for patients with narcolepsy: WSS narcolepsy task force. (2021) (2)
Identifying the best biomarkers for α-synucleinopathies (2021) (2)
Changes in Sleep Pattern During the COVID-19 Lockdown in Patients With Narcolepsy, Idiopathic Hypersomnia, and Restless Legs Syndrome (2022) (2)
Dissemination of circulating tumor cells at night: role of sleep or circadian rhythm? (2022) (2)
Clinicopathologic Correlations in 172 Cases of REM Sleep Behavior Disorder ± a Coexisting Neurologic Disorder (PL01.003) (2013) (2)
Clinical neurophysiology of CNS hypersomnias. (2019) (2)
Erratum: HLA-DPB1 and HLA class i confer risk of and protection from narcolepsy (American Journal of Human Genetics (2015) 96 (136-146)) (2015) (2)
Comparing treatment effeCt measurements in narColepsy: (2017) (2)
0645 A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED-WITHDRAWAL, MULTICENTER STUDY ON THE EFFICACY AND SAFETY OF SODIUM OXYBATE IN PEDIATRIC SUBJECTS WITH NARCOLEPSY WITH CATAPLEXY (2017) (2)
Rotigotine in Patients with Restless Legs Syndrome and End-stage Renal Disease Requiring Hemodialysis (P7.298) (2015) (2)
Fine-mapping of SNCA in REM sleep behavior disorder and overt synucleinopathies (2019) (2)
0693 Effects Of Solriamfetol On 24-hour Blood Pressure Patterns In Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea (2020) (2)
0026 Strong Gene-Environment Interactions of Trank1 Gene Polymorphisms with Birth Difficulties in Kleine Levin Syndrome (2020) (2)
Corrigendum to “Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group” [Sleep Med 14(8) (2013) 795–806] (2014) (2)
Diurnal and Nocturnal Sleep in Narcolepsy with Cataplexy (2010) (2)
Is Restless Legs Syndrome Involved in Ambulation Related to Sleepwalking? (2016) (2)
Comment on the Letter to the Editor By Dr. Marcus on the Association between Narcolepsy and H1N1 Exposure (2011) (2)
Home nocturnal infrared video to record non‐rapid eye movement sleep parasomnias (2022) (2)
Heritability in chronic insomnia: commentary on Yun-Kwok Wing et al. familial aggregation and heritability of insomnia in a community-based study Sleep Med 2012. (2012) (2)
Familial Aggregation of Insomnia. (2016) (2)
Multiple treatment comparison in narcolepsy: a network meta-analysis-methodological concerns. (2019) (2)
0619 Solriamfetol (JZP-110) for Treatment of Excessive Sleepiness in Narcoleptic Patients With and Without Cataplexy: Results From a Randomized, Phase 3, Clinical Trial (2018) (2)
Acute Cardiovascular Care 2015 (2015) (2)
Erratum to: Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case–control study (2014) (2)
494 Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia (2021) (2)
Rare PSAP variants and possible interaction with GBA in REM sleep behavior disorder (2021) (2)
Reply to “Rigor, reproducibility and in vitro CSF assays: The devil in the details” (2017) (2)
Rapid eye movement sleep behavior disorder : devising controlled active treatment studies for symptomatic and neuroprotective therapy — a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder (2013) (2)
Dream‐enactment behaviours during the COVID‐19 pandemic: an international COVID‐19 sleep study (2022) (1)
0393 Weight Changes During Treatment With Lower-Sodium Oxybate in a Phase 3 Clinical Study in Patients With Narcolepsy (2022) (1)
INSOMNIA AND SLEEPINESS RISK FACTORS FOR DEPRESSION IN ELDERLY (2011) (1)
Prognostic Impact of Sleep Patterns and Related-Drugs in Patients with Heart Failure (2021) (1)
Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications (2022) (1)
Rapid eye movement sleep duration during the multiple sleep latency test to diagnose hypocretin-deficient narcolepsy. (2022) (1)
Shift workers are at increased risk of severe COVID-19 compared with day workers: Results from the international COVID sleep study (ICOSS) of 7141 workers (2022) (1)
485 Efficacy and Safety of Once- and Twice-Nightly Dosing of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia (2021) (1)
0740 Quality of Life in Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of JZP-258 in Adults with Narcolepsy with Cataplexy (2020) (1)
Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy (2022) (1)
Parasomnias in Narcolepsy with Cataplexy (2011) (1)
SMPD1 variants do not have a major role in REM sleep behavior disorder (2020) (1)
Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model for narcolepsy. (2022) (1)
Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial (2023) (1)
GBA Mutations in REM Sleep Behavior Disorder and Parkinson’s Disease (S19.007) (2016) (1)
Systematic assessment of autonomic symptoms in restless legs syndrome. (2021) (1)
Chapter 22 – Human and Animal Genetics of Sleep and Sleep Disorders (2009) (1)
489 Pivotal Phase 3 Study of FT218, a Once-Nightly Sodium Oxybate Formulation, in Patients With Narcolepsy: REST-ON Primary Results (2021) (1)
Chapter 91 – Idiopathic Hypersomnia (2017) (1)
Does the adenosine deaminase (ADA) gene confer risk of sleepwalking? (2021) (1)
A Randomized, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Solriamfetol (JZP-110) for the Treatment of Excessive Sleepiness (ES) in Participants with Narcolepsy Types 1 and 2 (NT1/2) (CT.003) (2018) (1)
[Narcolepsy, from Westphal to hypocretin]. (2004) (1)
Incidence of narcolepsy after H 1 N 1 influenza and vaccinations (1)
Association of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's Disease (2020) (1)
Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study. (2023) (1)
Characteristics of narcolepsy according to the age of diagnosis (2013) (1)
Proteomic Biomarkers of Kleine-Levin Syndrome. (2022) (1)
Arousal Reactions in Sleepwalking and Night Terrors in Adults: The Role of Res- piratory Events PARASOMNIAS (2002) (1)
[Which pretherapeutic evaluation of a newly diagnosed patient with obstructive sleep apnea syndrome?]. (2010) (1)
Neurodegenerative diseases and sleep disorders (2003) (1)
344 Daridorexant Improves Total Sleep Time (TST) in Insomnia Patients Without Altering the Proportion of Sleep Stages (2021) (1)
Conflicts of interest-reply. (2012) (1)
The role of sleep and dreams in long-COVID. (2022) (1)
Sleepiness in adults: An umbrella review of a complex construct. (2022) (1)
INSOMNIA AND DAYTIME SLEEPINESS ARE RISK FACTORS FOR DEPRESSIVE SYMPTOMS IN THE ELDERLY (2011) (1)
Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia (2022) (1)
0753 Cataplexy-Free Days in a Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of JZP-258 in Adults With Narcolepsy With Cataplexy (2020) (1)
0950 Effects of Sodium Oxybate (SXB) on Body Mass Index (BMI) in Pediatric Patients With Narcolepsy (2020) (1)
The Genetic Basis of Sleep and Sleep Disorders: Heritability and genetic factors in chronic insomnia (2013) (1)
To Increase Our Knowledge on Sleep, Sleep Disorders, and Chronobiology in the Neuroscience Field during the Next Decade (2017) (1)
Narcolepsy, Idiopathic Hypersomnia, and Dysautonomia (2021) (1)
[DEFINITIONS AND EPIDEMIOLOGY OF EXCESSIVE SLEEPINESS]. (2016) (1)
Effect of sodium oxybate (SXB), modafinil and combination on disrupted nighttime sleep in narcolepsy (2013) (1)
0752 JZP-258 Dose Titration and Transition from Sodium Oxybate in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adult Participants With Narcolepsy With Cataplexy (2020) (1)
Ventricular Remodeling after Myocardial Infarct: A Minireview on the Impact of Obstructive Sleep Apnea Syndrome (2015) (1)
Idiopathic Hypersomnia Severity Scale (2020) (1)
Decision making and addictive behaviors in narcolepsy with cataplexy (2013) (1)
NPC1 variants are not associated with Parkinson’s disease, REM-sleep behavior disorder or dementia with Lewy bodies in European cohorts (2020) (1)
Aspects immunologiques de la narcolepsie (2001) (1)
0623 Long-Term Evaluation of Safety and Efficacy of Pitolisant In Narcolepsy: Harmony III Study (2018) (1)
500 Correlation of the Idiopathic Hypersomnia Severity Scale With Other Measures of Sleep Parameters in a Phase 3 Trial (2021) (1)
Analysis of dominant and recessive parkinsonism genes in REM sleep behavior disorder (2020) (0)
NARCOLEPSY-CATAPLEXY, A DISEASE CAUSED BY THE LOSS OF ~70,000 HYPOCRETIN CELLS IN THE HY- (2010) (0)
P003 Randomised, placebo-controlled study of solriamfetol for excessive daytime sleepiness in narcolepsy types 1/2 (2019) (0)
[Excessive sleepiness: 10 key messages]. (2016) (0)
ADHD SYMPTOMS IN PEDIATRIC NARCOLEPSY Attention-Deficit / Hyperactivity Disorder ( ADHD ) Symptoms in Pediatric Narcolepsy : A Cross-Sectional Study (2015) (0)
Regional changes in brain perfusion during REM sleep in patients with Alzheimer's disease (2009) (0)
Daridorexant (ACT-541468), a new dual orexin receptor antagonist, for the treatment of insomnia disorder in the elderly: results from a randomized, double-blind, placebo-controlled, 5-period, 5-treatment crossover dose-response phase 2 study (2019) (0)
QUANTIFICATION OF HEPCIDIN-25 IN HUMAN CEREBROSPINAL FLUID: TECHNICAL FEASIBILITY AND BIOLOGICAL RELEVANCE IN NEURODEGENERATIVE DISEASES (2017) (0)
Kinesthetic stimulation for obstructive sleep apnea syndrome: An “on-off” proof of concept trial (2018) (0)
Somnolence diurne excessive et maladie de Parkinson (MP) (2015) (0)
CANADIAN CONSORTIUM ON NEURODEGENERATION IN AGING (CCNA) (2022) (0)
Pitolisant efficacy on cataplexy: a double blind, randomised, placebo controlled trial in patients with narcolepsy (the HARMONY-CTP trial) (2017) (0)
DECISION MAKING IN NARCOLEPSY WITH CATAPLEXY Decision Making in Narcolepsy with Cataplexy (2010) (0)
Effort-based decision making in narcolepsy-cataplexy (2013) (0)
Editorial: Neurobiology of sleeping behaviors (2023) (0)
Genetic Regulation of Sleep (2004) (0)
Author response: Comorbidity between central disorders of hypersomnolence and immune-based disorders (2017) (0)
050 Ischaemic arterial strokes in childhood: Importance of idiopathic forms (1999) (0)
Edinburgh Research Explorer Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index (2017) (0)
Sleep disorders and their effects on the elderly, with regard to healthy, dependent and fragile populations (2009) (0)
Maintenance of Wakefulness Test, real and simulated driving in narcolepsy/hypersomnia patients (2018) (0)
A new incidence peak of childhood narcolepsy type 1 in 2013: a new perspective on the role of influenza virus? (2020) (0)
0407 ACT-541468, A Dual Orexin Receptor Antagonist, For The Treatment Of Insomnia Disorder: A Randomized, Double-Blind, Placebo-Controlled, 5-Period, 5-Treatment Crossover Dose-Response Phase 2 Study In The Elderly (2019) (0)
Predictors of Neurodegeneration in Idiopathic REM sleep behavior disorder: a multicenter cohort study (CCI.003) (2018) (0)
Efficacy and safety of pitolisant in patients with narcolepsy: a review of clinical trials (2019) (0)
Author Correction: Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise (2020) (0)
Retinoic Acid Signaling Affects (2005) (0)
Association of rare variants in ARSA with Parkinson’s disease (2023) (0)
Chapter 4 The major physiological functions during sleep (2003) (0)
Rare TMEM230 Variants are Potentially Associated With Early Onset Parkinson’s Disease (P3-11.013) (2023) (0)
[Role and actions of the orphan rare diseases reference center for central hypersomnias in France]. (2013) (0)
DECISION-MAKING AND REWARD-SEEKING IN DOPAMINE AGONIST THERAPY FOR RLS (2013) (0)
0375 A Novel Dual Orexin Receptor Antagonist (ACT-541468) to Treat Insomnia: A Randomized, Double-Blind, Placebo-Controlled, Active-Reference Phase 2 Study (2019) (0)
Efficacy of Once-Nightly Sodium Oxybate (ON-SXB; FT218) Across Stimulant Use Subgroups: Post-hoc Analyses From the REST-ON Trial (2022) (0)
0766 Evaluation Of Cataplexy-free Days In Children/Adolescents With Narcolepsy With Cataplexy Treated With Sodium Oxybate (2019) (0)
[Sleep disorders in children and adults]. (2014) (0)
Cataplexy-free days following sodium oxybate treatment in children/adolescents with narcolepsy with cataplexy (2019) (0)
SLEEP AND BRAIN AMYLOID LOAD IN FRAIL PARTICIPANTS: A COMPLEX RELATIONSHIP (2018) (0)
and mobility impairment Human skeletal muscle metabolic economy in vivo: effects of contraction intensity, age, (2015) (0)
Trajectories of daytime sleepiness and sleep duration before diagnosis of dementia: A 14‐year follow‐up study (2021) (0)
Machine learning model on polysomnography features throughout the night to better characterize narcolepsy type 1 (2022) (0)
Patients disrupted Nighttime sleep in Narcolepsy (0)
Evolution of the clinical and polysomnographic picture of childhood narcolepsy with cataplexy following disease onset (2013) (0)
0813 Sodium Oxybate Treatment of Narcolepsy in Pediatric Patients: Long-term Efficacy and Safety (2018) (0)
Trajectories of sleep duration and timing prior to dementia: a 14-year follow-up study (2022) (0)
Diagnostic de l’hypersomnie idiopathique via un protocole d’enregistrement de 32 heures en condition bedrest (2018) (0)
Exploration of cardiac autonomic function by myocardial 123-I-MIBG scintigraphy in narcolepsy type 1 (2017) (0)
[Nontraumatic coma]. (2012) (0)
Responsiveness of Daytime Sleepiness and Fatigue Scales in Myotonic Dystrophy Type 1 (2021) (0)
INSOMNIA IS A COMMON COMPLAINT IN THE GENERAL POPULATION.1 THE DIAGNOSIS OF INSOMNIA INVOLVES (2007) (0)
0768 Time Course Of Improvement In Excessive Daytime Sleepiness And Cataplexy During Treatment With Pitolisant In Patients With Narcolepsy (2020) (0)
Interactions between sleep and pain: the case of fibromyalgia (2007) (0)
Pitolisant Evaluation in Patients with OSA and Treated by NCPAP but Still Complaining of Excessive Daytime Sleepiness (EDS) Eudract n°: 2009-017248-14 (2020) (0)
Neural network analysis of sleep stages enables efcient diagnosis of narcolepsy (2018) (0)
[How to manage daytime sleepiness associated with Parkinson's disease]. (2010) (0)
Orexi: A the missing link in the amyloid process? (2015) (0)
Unsupervised clustering of central hypersomnolence disorders enables data-driven phenotyping: toward more reliable diagnostic criteria (2022) (0)
Periodic leg movements of sleep in narcoleptic patients with or without restless legs syndrome (2010) (0)
HLA in isolated REM sleep behavior disorder and Lewy body dementia (2023) (0)
Novel associations of BST1 and LAMP3 with rapid eye movement sleep behavior disorder (2020) (0)
Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy (2018) (0)
0389 Efficacy of Lower-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Response Based on the Epworth Sleepiness Scale Score (2022) (0)
Restlesslegs syndrom (2017) (0)
Hypersomnia and Narcolepsy (2012) (0)
14. Resting sympathetic and cardiovascular activities during wake in narcolepsy with cataplexy (2015) (0)
Insomnia: so frequent and insufficiently supported (2017) (0)
Pitolisant efficacy in excessive daytime sleepiness for patients with obstructive sleep apnea (2021) (0)
Iconography : Decreased fat oxidation during exercise in severe obstructive sleep apnoea syndrome (2012) (0)
Insomnia: 10 key messages (2017) (0)
Correction to: Changes in Cataplexy Frequency in a Clinical Trial of Lower‑Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications (2022) (0)
0772 Effects Of Solriamfetol On 24-hour Blood Pressure Patterns In Participants With Excessive Daytime Sleepiness Associated With Narcolepsy (2020) (0)
Cognitive strategies to improve symptoms of restless legs syndrome. (2022) (0)
Narcolepsy with Cataplexy: Hypocretin and Immunological Aspects (2007) (0)
Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning (2018) (0)
Idling for decades: a European study on risk factors associated with long time to narcolepsy diagnosis (2022) (0)
CSF OREXIN-A/HYPOCRETIN-1 CHANGES IN THE ALZHEIMER DISEASE PROCESS (2016) (0)
Corrigendum: Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy (2011) (0)
[Introduction to the thematic series: "Sleep"]. (2013) (0)
Cardiac Sympathetic Activity differentiates Idiopathic and Symptomatic Rapid Eye Movement Sleep Behaviour Disorder (2018) (0)
Update on the treatment of idiopathic hypersomnia: Progress, challenges, and expert opinion. (2023) (0)
[Potential teratogenicity of modafinil - conflicting evidence, need for research]. (2023) (0)
Long-term evaluation of safety and efficacy of pitolisant in narcolepsy: harmony 3 study (2019) (0)
Incidence, worsening and risk factors of daytime sleepiness in a population-based 5-year longitudinal study (2017) (0)
[Genetics of human narcolepsy]. (2001) (0)
Chapter 41. Narcolepsy (2008) (0)
0618 Cerebrospinal Fluid Biomarkers in Kleine-Levin syndrome (2018) (0)
P.1.g.085 Gap junction-mediated modulation of modafinil pharmacological profile (2014) (0)
P15.9 Sympathetic skin response in narcolepsy cataplexy: preliminary results (2011) (0)
Hepcidin and ferritin levels in restless legs syndrome: a case–control study (2020) (0)
Nocturnal sleep fragmentation and CSF orexin levels in humans: sleep and wake bouts (2019) (0)
The dementia-associated APOE ε 4 allele is not associated with REM sleep behavior disorder (2017) (0)
DQB1 LOCUS AND THE RISK AND PROTECTION IN NARCOLEPSY WITH CATAPLEXY (2013) (0)
495 Efficacy of Lower-Sodium Oxybate on Idiopathic Hypersomnia, Measured by the Idiopathic Hypersomnia Severity Scale (2021) (0)
Sleep and cognitive decline in the elderly: The French Three-City Cohort (2012) (0)
[Sleep disorders in children and adults]. (2003) (0)
REM Sleep Behavior Disorder in Narcolepsy with Cataplexy (2010) (0)
LETTER TO THE EDITOR Ictal SPECT in patients with rapid eye movement sleep behaviour disorder (2015) (0)
490 Efficacy of FT218 on Polysomnographic Measures of Sleep Continuity in Patients With Narcolepsy: Results From the REST-ON Trial (2021) (0)
Revised diagnostic criteria for idiopathic hypersomnia: a 32-hour bed-rest protocol (2017) (0)
Confirmation of absence of GABA‐A receptor potentiation in idiopathic hypersomnia (2017) (0)
Incidence and duration of common adverse events in 2 solriamfetol phase 3 studies for treatment of excessive daytime sleepiness in obstructive sleep apnoea and narcolepsy (2019) (0)
Genotype-Phenotype correlation in Parkin-Parkinson’s disease (P3-11.012) (2023) (0)
Parkinson’s Disease Genetic Loci in Rapid Eye Movement Sleep Behavior Disorder (2015) (0)
[EXCESSIVE SLEEPINESS]. (2016) (0)
Sleep complaints and cardio-cerebrovascular diseases in the elderly: A 6-year prospective study (2013) (0)
Autonomic Dysfunction in Hypersomnia (2023) (0)
Comments on the Letter to the Editor by Ferri et al. on Autonomic Response to Periodic Leg Movements in Sleep in Narcolepsy-Cataplexy. (2011) (0)
The Bordeaux Sleepiness Scale (BOSS): a new questionnaire to measure sleep-related driving risk. (2023) (0)
487 Effect of Lower-Sodium Oxybate on Sleep Inertia in Idiopathic Hypersomnia in a Double-Blind, Randomized Withdrawal Study (2021) (0)
0621 Measures of Function, Work Productivity, and Quality of Life From a Phase 3 Study of Solriamfetol (JZP-110) in Patients with Narcolepsy (2018) (0)
Efficacy of Low-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Treatment Response Based on the Epworth Sleepiness Scale and Idiopathic Hypersomnia Severity Scale Scores (S6.009) (2023) (0)
0409 Self-perceived sleep during the Maintenance of Wakefulness Test: how does it predict accidental risk in patients with sleep disorders? (2022) (0)
M-N-126 RETROSPECTIVE EVALUATION OF PREGNANCIES IN EUROPEAN NARCOLEPTICWOMEN (2011) (0)
[Vaccination anti-H1N1 and narcolepsy]. (2011) (0)
Sequencing the entire exome of REM sleep behavior and progression to neurodegenerative diseases (2020) (0)
Effect of sodium oxybate on sleep stage shifts and sleep quality in patients with narcolepsy (2013) (0)
Effects of daridorexant on total sleep time (TST) and sleep stage proportions in patients with insomnia disorder (2022) (0)
Has the COVID-19 Pandemic Traumatized Us Collectively? The Impact of the COVID-19 Pandemic on Mental Health and Sleep Factors via Traumatization: A Multinational Survey (2022) (0)
Impact of a telerehabilitation programme combined with continuous positive airway pressure on symptoms and cardiometabolic risk factors in obstructive sleep apnea patients (2023) (0)
0785 Sodium Oxybate Treatment of Pediatric Narcolepsy: Effects on Weight, Height, and Pubertal Development (2018) (0)
[MANAGEMENT OF CENTRAL HYPERSOMNIAS]. (2016) (0)
Where and what is the PPN and what is its role in locomotion (2015) (0)
Persistent short nighttime sleep duration is associated with a greater post-COVID risk in fully mRNA-vaccinated individuals (2023) (0)
Efficacy and Safety of Pitolisant in Patients With Narcolepsy: A Review of Clinical Trials (P3.6-034) (2019) (0)
0401 Efficacy of Once-Nightly Sodium Oxybate (ON-SXB; FT218) By Narcolepsy Type: Post-hoc Analyses From the REST-ON Trial (2022) (0)
Hypercapnic ventilatory response in patients with Steinert's myotonic dystrophy type 1 (2013) (0)
Impact of Obstructive Sleep Apnea Syndrome on Ventricular Remodeling after Acute Myocardial Infarction: A Proof-of-Concept Study (2022) (0)
Regional changes in brain perfusion during REM sleep in patients with Alzheimer's disease (2009) (0)
Brain-derived neurotrophic factor (BDNF) variants and promoter I methylation are associated with prolonged nocturnal awakenings in older adults. (2023) (0)
GBA variants in REM sleep behavior disorder risk and conversion: a multicenter study (2020) (0)
Hypocretin in Neuropsychiatric Disorders (2005) (0)
Classification of Narcolepsy with Cataplexy versus Narcolepsy without Cataplexy, and Narcolepsy type 1 versus Narcolepsy type 2 : a machine learning approach (2016) (0)
0387 Weight Changes During Treatment With Lower-Sodium Oxybate in a Phase 3 Clinical Study in Patients With Idiopathic Hypersomnia (2022) (0)
How to evaluate sleepiness in Parkinson’s disease? (2013) (0)
Cerebrospinal fluid proteomics in recent-onset Narcolepsy type 1 reveals activation of the complement system (2023) (0)
Car Crashes and Central Disorders of Hypersomnolence (2016) (0)
University of Groningen Novel approach identifies SNPs in SLC2A10 and KCNK9 with evidence for parent-of-origin effect on body mass index Hoggart, (2014) (0)
Diagnostic Algorithm for Hypersomnias (2013) (0)
Pitolisant long term effect in sleepy obstructive sleep apnea patients with CPAP (2021) (0)
Early Daytime Sleepiness and Nighttime Slow-wave Sleep Disorganization in Progressive Macaque Model of Parkinson’s Disease (2022) (0)
[Narcolepsy type 1: a relationship with H1N1 vaccination]. (2016) (0)
Author Correction: Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise (2020) (0)
Author reply to Dr. Peraita-Adrados (2019) (0)
SLEEPINESS AND REM SLEEP IN MYOTONIC DYSTROPHY Daytime Sleepiness and REM Sleep Characteristics in Myotonic Dystrophy: A Case-Control Study (2011) (0)
Pitolisant safety and efficacy in adult narcoleptic patients with or without cataplexy or idiopathic hypersomnia patients in a compassionate use program in france: autorisation temporaire d'utilisation de cohorte (ATUc) (2017) (0)
Long-term evaluation of safety and efficacy of pitolisant (wakix ® ), an histamine H3R antagonist, in narcolepsy (2017) (0)
Effects of daridorexant and zolpidem on night wakefulness in adults with insomnia: exploratory analysis from a randomized, double-blind, placebo-controlled phase 2 trial (2022) (0)
DOES EXCESSIVE DAYTIME SLEEPINESS AFFECT RISK FOR COGNITIVE DECLINE IN FRAIL INDIVIDUALS? (2016) (0)
AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders (2019) (0)
0750 Nocturnal Sleep Stability and Cerebrospinal Fluid Orexin-A Levels: Sleep and Wake Bouts (2020) (0)
New video-polysomnographic criteria for the diagnosis of disorders of arousal (2017) (0)
[CLINICAL INVESTIGATION OF AN EXCESSIVE SLEEPINESS COMPLAINT]. (2016) (0)
Reliability of wrist‐worn accelerometry devices and algorithms for sleep detection (2020) (0)
Ask-the-Expert Education in Insomnia Significantly Improves Knowledge and Competence for Non-Sleep Experts (2022) (0)
488 REST-ON: Efficacy of FT218 for Daytime Sleepiness, Sleep Quality, Hallucinations, and Sleep Paralysis in Patients With Narcolepsy (2021) (0)
Narcolepsy (2022) (0)
Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly (2022) (0)
Erratum to "Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder". (2020) (0)
Daridorexant (Act-541468), a new dual orexin receptor antagonist, for the treatment of insomnia disorder: a randomized, double-blind, placebo-controlled, active-reference phase 2 study (2019) (0)
Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort (2023) (0)
Trajectories of sleep duration and timing before dementia: a 14-year follow-up study. (2022) (0)
Effects of sodium oxybate treatment on sleep architecture in paediatric patients with narcolepsy (2019) (0)
TOX3 Variants Are Involved in Restless Legs Syndrome and Parkinson’s Disease with Opposite Effects (2018) (0)
[First Nobel Prize for chronobiology]. (2018) (0)
How real road-driving performance, simulated driving performance, and maintenance of wakefulness test are related in narcolepsy/hypersomnia patients? (2017) (0)
Long-Term Maintenance of Efficacy and Safety of Pitolisant in the Treatment of Residual Sleepiness in Patients With Obstructive Sleep Apnoea (2023) (0)
The value of treatment of restless legs syndrome: socio-economic impact of RLS and of inadequate diagnosis and treatment across different healthcare systems (2017) (0)
Original Investigation Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial (2016) (0)
Efficacy of long-term treatment with daridorexant in patients with insomnia disorder on sleep and daytime functioning: a post-hoc analysis (2022) (0)
management of sleep disorders in the elderly (2010) (0)
EXECUTIVE FUNCTIONS IN NARCOLEPSY (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Yves A. Dauvilliers?

Yves A. Dauvilliers is affiliated with the following schools:

University of Lausanne
University of Montpellier
Stanford University

Yves A. Dauvilliers's Academic­Influence.com Rankings

Yves A. Dauvilliers's Degrees

Why Is Yves A. Dauvilliers Influential?

Yves A. Dauvilliers's Published Works

Published Works

What Schools Are Affiliated With Yves A. Dauvilliers?

Yves A. Dauvilliers's AcademicInfluence.com Rankings